| |
| |
|
| Insider
Information: |
Van Deventer Sander |
| Relationship: |
Director |
| City: |
1411 Dc Naarden |
| State: |
P7 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
69,141 |
|
|
Indirect Shares
|
6,209,820 |
|
|
| Direct
Value |
$289,170 |
|
|
|
Indirect Value
|
$378,247 |
|
|
| Total
Shares |
6,278,961 |
|
|
| Total
Value |
$667,417 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -38.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Argos Therapeutics Inc |
ARGS |
Director, 10% Owner |
2016-09-30 |
5,057 |
2016-08-02 |
6,199,961 |
Premium* |
|
|
uniQure B.V. |
QURE |
EVP, Research & Produc... |
2020-02-27 |
61,599 |
2020-02-27 |
9,859 |
Premium* |
|
|
Hookipa Pharma Inc. |
HOOK |
Director |
2020-10-21 |
2,485 |
2020-10-21 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
18 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HOOK |
Hookipa Pharma Inc. |
Director |
– • – |
2020-10-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,485 |
2,485 |
0 |
- |
|
| QURE |
uniQure B.V. |
EVP, Research & Product Dev. |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,380 |
61,599 |
0 |
- |
|
| QURE |
uniQure B.V. |
EVP, Research & Product Dev. |
• – – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
6,092 |
49,219 |
0 |
- |
|
| QURE |
uniQure B.V. |
EVP, Research & Product Dev. |
• – – |
2020-01-28 |
4 |
S |
$61.27 |
$137,214 |
D/D |
(2,227) |
43,127 |
0 |
% |
|
| QURE |
uniQure B.V. |
EVP, Research & Product Dev. |
• – – |
2019-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
45,354 |
0 |
- |
|
| QURE |
uniQure B.V. |
Chief Scientific Officer |
• – – |
2019-01-28 |
4 |
S |
$31.31 |
$42,519 |
D/D |
(1,358) |
40,313 |
0 |
- |
|
| QURE |
uniQure B.V. |
Chief Scientific Officer |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
I/I |
16,502 |
41,571 |
0 |
- |
|
| QURE |
uniQure B.V. |
Chief Scientific Officer |
• – – |
2018-01-29 |
4 |
S |
$18.53 |
$110,902 |
I/I |
(5,985) |
25,069 |
0 |
- |
|
| QURE |
uniQure B.V. |
Chief Scientific Officer |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
I/I |
7,795 |
31,054 |
0 |
- |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2017-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,859 |
|
- |
|
| ARGS |
Argos Therapeutics Inc |
Director |
– • • |
2016-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,263 |
5,057 |
0 |
- |
|
| ARGS |
Argos Therapeutics Inc |
Director |
– • • |
2016-08-02 |
4 |
B |
$0.00 |
$0 |
I/I |
1,545,454 |
6,199,961 |
2.17 |
- |
|
| ARGS |
Argos Therapeutics Inc |
Director |
– • • |
2016-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,427 |
2,794 |
0 |
- |
|
| ARGS |
Argos Therapeutics Inc |
Director |
– • • |
2016-06-29 |
4 |
B |
$0.00 |
$0 |
I/I |
1,322,618 |
4,654,507 |
2.17 |
- |
|
| ARGS |
Argos Therapeutics Inc |
Director |
– • • |
2016-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,367 |
1,367 |
0 |
- |
|
| ARGS |
Argos Therapeutics Inc |
Director |
– • • |
2016-03-14 |
4 |
B |
$0.00 |
$0 |
I/I |
881,745 |
3,331,889 |
2.17 |
- |
|
| ARGS |
Argos Therapeutics Inc |
Director |
– • • |
2014-02-12 |
4 |
B |
$8.00 |
$291,328 |
I/I |
36,416 |
2,450,144 |
2.25 |
- |
|
| ARGS |
Argos Therapeutics Inc |
Director |
– • • |
2014-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
2,413,728 |
2,413,728 |
0 |
- |
|
18 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
